procizumab (AK1967) / 4TEEN4 Pharmaceuticals - LARVOL DELTA

One Enzyme, Many Faces: The Expanding Role of DPP3 in Cardiovascular and Critical Care. (PubMed, J Clin Med) - "This review outlines the physiological mechanisms, clinical implications, and emerging therapeutic potential of DPP3 in cardiovascular and critical care. Ongoing trials with Procizumab will clarify whether neutralizing cDPP3 can improve outcomes in patients with cardiogenic and septic shock."

Journal • Review • Acute Coronary Syndrome • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Critical care • Heart Failure • Infectious Disease • Inflammation • Novel Coronavirus Disease • Septic Shock

PROCARD 1b: Procizumab (PCZ; AK1967) in Critical Cardiovascular Care (clinicaltrials.gov) - P1/2 | N=130 | Recruiting | Sponsor: 4TEEN4 Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular

PROCARD 1b: Procizumab (PCZ; AK1967) in Critical Cardiovascular Care (clinicaltrials.gov) - P1/2 | N=130 | Recruiting | Sponsor: 4TEEN4 Pharmaceuticals GmbH | Initiation date: Mar 2026 ➔ Jul 2025

Trial initiation date • Cardiovascular

PROCARD 1b: Procizumab (PCZ; AK1967) in Critical Cardiovascular Care (clinicaltrials.gov) - P1/2 | N=130 | Not yet recruiting | Sponsor: 4TEEN4 Pharmaceuticals GmbH | Initiation date: Apr 2025 ➔ Jul 2025

Trial initiation date • Cardiovascular